PDF(Pubmed)
Abstract：
Melatonin\'s cytoprotective properties may have therapeutic implications in treating ocular diseases like glaucoma and age-related macular degeneration. Literature data suggest that melatonin could potentially protect ocular tissues by decreasing the production of free radicals and pro-inflammatory mediators. This study aims to summarize the screened articles on melatonin\'s clinical, pharmacological, and formulation evaluation in treating ocular disorders. The identification of relevant studies on the topic in focus was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. The studies were searched in the following databases and web search engines: Pubmed, Scopus, Science Direct, Web of Science, Reaxys, Google Scholar, Google Patents, Espacenet, and Patentscope. The search time interval was 2013-2023, with the following keywords: melatonin AND ocular OR ophthalmic AND formulation OR insert AND disease. Our key conclusion was that using melatonin-loaded nano-delivery systems enabled the improved permeation of the molecule into intraocular tissues and assured controlled release profiles. Although preclinical studies have demonstrated the efficacy of developed formulations, a considerable gap has been observed in the clinical translation of the results. To overcome this failure, revising the preclinical experimental phase might be useful by selecting endpoints close to clinical ones.
摘要：
褪黑素的细胞保护特性可能对治疗青光眼和年龄相关性黄斑变性等眼部疾病具有治疗意义。文献数据表明，褪黑激素可以通过减少自由基和促炎介质的产生来潜在地保护眼组织。本研究旨在总结褪黑素临床筛选的文章,药理学,和制剂评估在治疗眼部疾病中的作用。根据系统审查和荟萃分析的首选报告项目（PRISMA2020）指南，确定了有关重点主题的相关研究。这些研究在以下数据库和网络搜索引擎中进行了搜索：Pubmed，Scopus,科学直接，WebofScience,Reaxys,谷歌学者，谷歌专利,Espacenet,和专利范围。搜索时间间隔为2013-2023年，具有以下关键词：褪黑激素和眼部或眼科和制剂或插入和疾病。我们的关键结论是，使用褪黑激素负载的纳米递送系统可以改善分子向眼内组织的渗透并确保受控释放曲线。尽管临床前研究已经证明了开发制剂的功效，在结果的临床翻译中观察到相当大的差距。为了克服这种失败，通过选择接近临床终点的终点，修改临床前实验阶段可能是有用的。
